You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCryptenamine
Accession NumberDB00785  (APRD00890)
TypeSmall Molecule
GroupsApproved
DescriptionCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
UnitensenMEDA AB
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQVO4N8484O
CAS number1356-18-9
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationFor the treatment of hypertension.
PharmacodynamicsCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.
Mechanism of actionCryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known. Some evidence has suggested that cryptenamine acts in a similar fashion to atropine, which lowers the "rest and digest" activity of all muscles and glands regulated by the parasympathetic nervous system. This occurs because atropine is a competitive inhibitor of the muscarinic acetylcholine receptors (acetylcholine is the neurotransmitter used by the parasympathetic nervous system). Therefore muscarinic acetylcholine receptors will be listed as experimental targets for cryptenamine.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Medpointe pharmaceuticals medpointe healthcare inc
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis Reference

Cavallito ,C.J.; US. Patent 2,789,977; April 23,1957; assigned to Innrin, Neisler and Company.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Cryptenamine.
AcebutololCryptenamine may increase the hypotensive activities of Acebutolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Cryptenamine.
AliskirenCryptenamine may increase the hypotensive activities of Aliskiren.
AlprenololCryptenamine may increase the hypotensive activities of Alprenolol.
AmbrisentanCryptenamine may increase the hypotensive activities of Ambrisentan.
AmifostineCryptenamine may increase the hypotensive activities of Amifostine.
AmlodipineAmlodipine may increase the hypotensive activities of Cryptenamine.
AtenololAtenolol may increase the hypotensive activities of Cryptenamine.
BenazeprilBenazepril may increase the hypotensive activities of Cryptenamine.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Cryptenamine.
BenmoxinBenmoxin may increase the hypotensive activities of Cryptenamine.
BepridilCryptenamine may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Cryptenamine.
BethanidineBethanidine may increase the hypotensive activities of Cryptenamine.
BimatoprostCryptenamine may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Cryptenamine.
BosentanBosentan may increase the hypotensive activities of Cryptenamine.
BretyliumCryptenamine may increase the hypotensive activities of Bretylium.
BrimonidineCryptenamine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Cryptenamine.
BupranololCryptenamine may increase the hypotensive activities of Bupranolol.
CandesartanCryptenamine may increase the hypotensive activities of Candesartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Cryptenamine.
CaptoprilCryptenamine may increase the hypotensive activities of Captopril.
CaroxazoneCaroxazone may increase the hypotensive activities of Cryptenamine.
CarteololCarteolol may increase the hypotensive activities of Cryptenamine.
CarvedilolCryptenamine may increase the hypotensive activities of Carvedilol.
CeliprololCryptenamine may increase the hypotensive activities of Celiprolol.
ChlorothiazideCryptenamine may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Cryptenamine.
CilazaprilCryptenamine may increase the hypotensive activities of Cilazapril.
ClonidineClonidine may increase the hypotensive activities of Cryptenamine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Cryptenamine.
DebrisoquinCryptenamine may increase the hypotensive activities of Debrisoquin.
DeserpidineCryptenamine may increase the hypotensive activities of Deserpidine.
DiazoxideDiazoxide may increase the hypotensive activities of Cryptenamine.
DiltiazemDiltiazem may increase the hypotensive activities of Cryptenamine.
DorzolamideCryptenamine may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Cryptenamine.
EfonidipineCryptenamine may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Cryptenamine.
EnalaprilatCryptenamine may increase the hypotensive activities of Enalaprilat.
EpoprostenolCryptenamine may increase the hypotensive activities of Epoprostenol.
EprosartanCryptenamine may increase the hypotensive activities of Eprosartan.
FelodipineCryptenamine may increase the hypotensive activities of Felodipine.
FenoldopamCryptenamine may increase the hypotensive activities of Fenoldopam.
FosinoprilFosinopril may increase the hypotensive activities of Cryptenamine.
FurazolidoneFurazolidone may increase the hypotensive activities of Cryptenamine.
GuanabenzGuanabenz may increase the hypotensive activities of Cryptenamine.
GuanadrelGuanadrel may increase the hypotensive activities of Cryptenamine.
GuanethidineCryptenamine may increase the hypotensive activities of Guanethidine.
GuanfacineCryptenamine may increase the hypotensive activities of Guanfacine.
HexamethoniumCryptenamine may increase the hypotensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypotensive activities of Cryptenamine.
HydralazineCryptenamine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideCryptenamine may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Cryptenamine.
IloprostIloprost may increase the hypotensive activities of Cryptenamine.
IndapamideCryptenamine may increase the hypotensive activities of Indapamide.
IndenololCryptenamine may increase the hypotensive activities of Indenolol.
IndoraminCryptenamine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Cryptenamine.
IproniazidIproniazid may increase the hypotensive activities of Cryptenamine.
IrbesartanCryptenamine may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cryptenamine.
IsradipineIsradipine may increase the hypotensive activities of Cryptenamine.
LabetalolLabetalol may increase the hypotensive activities of Cryptenamine.
LacidipineCryptenamine may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Cryptenamine.
LercanidipineLercanidipine may increase the hypotensive activities of Cryptenamine.
LisinoprilLisinopril may increase the hypotensive activities of Cryptenamine.
LofexidineCryptenamine may increase the hypotensive activities of Lofexidine.
LosartanLosartan may increase the hypotensive activities of Cryptenamine.
MacitentanCryptenamine may increase the hypotensive activities of Macitentan.
ManidipineCryptenamine may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Cryptenamine.
MecamylamineMecamylamine may increase the hypotensive activities of Cryptenamine.
MethyldopaCryptenamine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Cryptenamine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cryptenamine.
MetipranololCryptenamine may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Cryptenamine.
MetoprololMetoprolol may increase the hypotensive activities of Cryptenamine.
MibefradilCryptenamine may increase the hypotensive activities of Mibefradil.
MinaprineMinaprine may increase the hypotensive activities of Cryptenamine.
MinoxidilMinoxidil may increase the hypotensive activities of Cryptenamine.
MoclobemideMoclobemide may increase the hypotensive activities of Cryptenamine.
MoexiprilMoexipril may increase the hypotensive activities of Cryptenamine.
MolsidomineMolsidomine may increase the hypotensive activities of Cryptenamine.
MoxonidineCryptenamine may increase the hypotensive activities of Moxonidine.
NadololCryptenamine may increase the hypotensive activities of Nadolol.
NebivololCryptenamine may increase the hypotensive activities of Nebivolol.
NialamideNialamide may increase the hypotensive activities of Cryptenamine.
NicardipineNicardipine may increase the hypotensive activities of Cryptenamine.
NicorandilCryptenamine may increase the hypotensive activities of Nicorandil.
NiguldipineCryptenamine may increase the hypotensive activities of Niguldipine.
NilvadipineCryptenamine may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Cryptenamine.
NisoldipineNisoldipine may increase the hypotensive activities of Cryptenamine.
NitrendipineCryptenamine may increase the hypotensive activities of Nitrendipine.
NitroprussideNitroprusside may increase the hypotensive activities of Cryptenamine.
ObinutuzumabCryptenamine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Cryptenamine.
OlmesartanOlmesartan may increase the hypotensive activities of Cryptenamine.
OmapatrilatCryptenamine may increase the hypotensive activities of Omapatrilat.
OxprenololCryptenamine may increase the hypotensive activities of Oxprenolol.
PargylineCryptenamine may increase the hypotensive activities of Pargyline.
PenbutololCryptenamine may increase the hypotensive activities of Penbutolol.
PentoliniumCryptenamine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cryptenamine.
PerindoprilCryptenamine may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Cryptenamine.
PheniprazinePheniprazine may increase the hypotensive activities of Cryptenamine.
PhenoxybenzamineCryptenamine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cryptenamine.
PhentolaminePhentolamine may increase the hypotensive activities of Cryptenamine.
PinacidilCryptenamine may increase the hypotensive activities of Pinacidil.
PindololCryptenamine may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Cryptenamine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Cryptenamine.
PolythiazideCryptenamine may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Cryptenamine.
PropranololPropranolol may increase the hypotensive activities of Cryptenamine.
QuinaprilCryptenamine may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Cryptenamine.
RamiprilRamipril may increase the hypotensive activities of Cryptenamine.
RasagilineRasagiline may increase the hypotensive activities of Cryptenamine.
RemikirenRemikiren may increase the hypotensive activities of Cryptenamine.
RescinnamineCryptenamine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Cryptenamine.
RiociguatCryptenamine may increase the hypotensive activities of Riociguat.
RituximabCryptenamine may increase the hypotensive activities of Rituximab.
SafrazineSafrazine may increase the hypotensive activities of Cryptenamine.
SaprisartanCryptenamine may increase the hypotensive activities of Saprisartan.
SelegilineSelegiline may increase the hypotensive activities of Cryptenamine.
SelexipagCryptenamine may increase the hypotensive activities of Selexipag.
SildenafilSildenafil may increase the antihypertensive activities of Cryptenamine.
SitaxentanCryptenamine may increase the hypotensive activities of Sitaxentan.
SpiraprilCryptenamine may increase the hypotensive activities of Spirapril.
TadalafilTadalafil may increase the antihypertensive activities of Cryptenamine.
TelmisartanCryptenamine may increase the hypotensive activities of Telmisartan.
TemocaprilCryptenamine may increase the hypotensive activities of Temocapril.
TerlipressinCryptenamine may increase the hypotensive activities of Terlipressin.
TiboloneCryptenamine may increase the hypotensive activities of Tibolone.
TicrynafenCryptenamine may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Cryptenamine.
TolazolineCryptenamine may increase the hypotensive activities of Tolazoline.
ToloxatoneToloxatone may increase the hypotensive activities of Cryptenamine.
TorasemideTorasemide may increase the hypotensive activities of Cryptenamine.
TrandolaprilTrandolapril may increase the hypotensive activities of Cryptenamine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cryptenamine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Cryptenamine.
TravoprostTravoprost may increase the hypotensive activities of Cryptenamine.
TreprostinilTreprostinil may increase the hypotensive activities of Cryptenamine.
TrichlormethiazideCryptenamine may increase the hypotensive activities of Trichlormethiazide.
TrimazosinCryptenamine may increase the hypotensive activities of Trimazosin.
TrimethaphanCryptenamine may increase the hypotensive activities of Trimethaphan.
UdenafilUdenafil may increase the antihypertensive activities of Cryptenamine.
UnoprostoneCryptenamine may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Cryptenamine.
VardenafilVardenafil may increase the antihypertensive activities of Cryptenamine.
XylometazolineCryptenamine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Cryptenamine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Jandhyala ML, Buckley JP: Mechanisms of action of cryptenamine. J Pharm Sci. 1968 Sep;57(9):1576-82. [PubMed:5674398 ]
  4. Jandhyala BS, Buckley JP: Pharmacology and mechanism of action of cryptenamine. J Pharm Sci. 1966 Sep;55(9):888-93. [PubMed:5918523 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23